



TECHNOLOGY EVALUATION CONSORTIUM™

Quantitative Medicine Meeting with Pfizer
Friday, June 14th, 2013
Webinar

Cambridge Healthtech Associates

Dawn Van Dam (General Manager)

Amid Zand (Project Manager)

Quantitative Medicine

John King

Scott Bodine

Geoff Hoare

Joshua Kangas

Robert Murphy

Jamie Grooms (not on call)

Jim Parrino (not on call)

David Demosthenes (not on call)

Pfizer

Yvonne Will

Nigel Greene

Falgun Shah (not on call)

Agenda

- I) Welcome: CHA – Dawn
 - II) One on One Discussion: Quantitative Medicine Slides
 - III) Q&A: Quantitative Medicine-Pfizer
 - IV) Closing and Action Items: Dawn
-

I) Welcome

Dawn explained that from this time forward, meetings would take place between Quantitative Medicine and each interested company individually, allowing for questions pertaining specifically to each company's potential project. Meeting participants were also made aware of the fact that the proceedings were being recorded and the people who would have access to the recordings.

Dawn addressed a question from John King.

Dawn's response to John: Yes, the recording will only be available to parties involved in this particular meeting. Other participants will have a similar discussion for their specific company.

II) One on One Discussion: Quantitative Medicine Slides

John King introduced the individuals that were present from Quantitative Medicine and welcomed Yvonne Will and Nigel Greene from Pfizer. John gave a brief introduction for Joshua Kangas before turning the meeting over to Josh to proceed with the Quantitative Medicine slides.

Josh: The presentation is intended to address three major questions and give descriptions of a demonstration study, as well as the type of retrospective study which would be conducted for the TEC directed effort.

Questions to be addressed:

1. "What makes Quantitative Medicine's process different from others?"
2. "How does the active learning process work?"

3. “For what size of experimental space can this process offer a benefit?”

Josh briefly explained several recent improvements in predictive modeling with regards to drug discovery and how Quantitative Medicine’s approach can help further capitalize on such improvements.

Discussion was directed through explanation of several of Quantitative Medicine’s various methodologies:

Making predictions based on assay results correlations

Making predictions based on compound result correlations

Making predictions based on compound features (QSAR)

Selecting experiments for confirmatory information

Selecting experiments to improve predictive model

The Pfizer team expressed significant skepticism in light of the lack of technical details and specificity provided by Quantitative Medicine’s presentation.

Josh described the TEC retrospective study including the general protocol, desirable characteristics of the dataset to be used, overall goals of the retrospective study, and data security.

III) Q&A: Quantitative Medicine-Pfizer

The Pfizer team asked for a concrete of example of the success of Quantitative Medicine’s approach.

Quantitative Medicine explained that they had not had an opportunity to demonstrate the approach outside of the simulation study described in the previous meeting, and would like to use data from Pfizer as an opportunity to offer a concrete illustration of the validity of the process.

The Pfizer team expressed concern about sharing proprietary compound structures as most of the compounds in their corporate library were not patented.

Quantitative Medicine explained the structure of their data security measures and the status of current interactions between information security entities at both Quantitative Medicine and Pfizer.

Nigel Greene explained that Pfizer does not have any available datasets relevant to drug safety that are of sufficient size or completeness; the greatest estimated degree of completeness being roughly 40%.

Pfizer and Quantitative Medicine discussed and clarified what the intended result of participation in a retrospective study would be.

IV) Closing and Action Items

Dawn and the Pfizer team planned to setup a meeting for the coming week. Dawn and the Pfizer team subsequently exited the teleconference.

The Quantitative Medicine team planned to contact Dawn to go over key points for her discussion with the Pfizer team. Quantitative Medicine then exited the teleconference.

The recording was ended and Amid, Dawn, and the Quantitative Medicine team entered a private discussion.